Timing, symptom burden and a prior blood clot, weighed for a composite 51-year-old under The Menopause Society's 2022 and 2023 statements, bring this NU576 plan to a nonhormonal treatment chosen by mechanism. Searches like "nu 576 unit 9 assignment example", "nu576 unit 9 sample" and "nu576 unit 9 example" land here.
Nine Hot Flashes a Day and a Clot in Her Past: A Menopause Care Plan That Weighs Hormones and Then Chooses Without Them
[Student Name]
Purdue University Global
NU576: NP II - Primary Care of Women's Health
Unit 9 Menopause Care Plan
[Instructor Name]
[Date]
The patient is a composite; doses, scores and dates are bracketed.
Timing
Ms. [W.], 51, a middle school principal. Last menstrual period 14 months ago. The 2022 hormone therapy statement finds benefit most likely to exceed risk when treatment starts before age 60 or in the first decade after the final period (North American Menopause Society, 2022). By timing alone, she is in the window where hormone therapy is usually a first choice.
Symptoms
Nine moderate to severe hot flashes a day by diary, several with drenching sweats; waking every two hours; fatigue affecting her work. Vaginal dryness with discomfort during sex. Mood steady. Her symptoms are frequent and severe enough to justify treatment.
Risk
Six years ago, a clot formed in the deep veins of her left calf after knee surgery, treated with anticoagulation for three months. No clots since. BMI [28]. Blood pressure [124/78]. No personal history of breast cancer; mammogram last year normal. Nonsmoker. A personal history of venous thromboembolism moves systemic estrogen out of first place, even for a woman whose age and timing would otherwise favor it. Oral estrogen raises clot risk, and a prior clot is a reason to avoid systemic hormone therapy or to consider it only after specialist review; transdermal estrogen carries less risk in observational data, but the evidence in women with a prior clot is limited (North American Menopause Society, 2022). She said she would prefer not to take a medicine that could cause another clot.
Options Considered
1. Systemic estrogen with a progestogen. Mechanism: replaces estrogen. Evidence: most effective for hot flashes. Fit: moved down by her prior clot; available only after hematology review if nonhormonal options fail.
2. Fezolinetant. Mechanism: blocks neurokinin 3 receptors in the hypothalamic thermoregulatory center, where estrogen loss leaves signaling unchecked. Evidence: in a phase 3 trial, women taking it had fewer and milder hot flashes than those on placebo at twelve weeks (Lederman et al., 2023). Fit: no estrogen, no known clot risk; requires liver tests.
3. Low-dose paroxetine. Mechanism: serotonergic modulation. Evidence: approved for vasomotor symptoms; modest effect. Fit: interacts with some medicines through CYP2D6.
4. Venlafaxine or escitalopram. Evidence: modest reduction in hot flashes. Fit: possible if mood symptoms arise.
5. Gabapentin at bedtime. Evidence: reduces hot flashes and may help sleep. Fit: sedation, dizziness.
6. Cognitive behavioral therapy and clinical hypnosis. Evidence: recommended nonhormonal options that reduce the bother of hot flashes (North American Menopause Society, 2023). Fit: no drug effects.
The Choice
Fezolinetant [45 mg] daily, with cognitive behavioral therapy for sleep. Fezolinetant targets the mechanism of her hot flashes directly without estrogen, and its trial evidence shows a larger effect than the older nonhormonal drugs. Before starting, liver tests are checked, because the drug carries a warning about liver injury; they are repeated at [one, two and three] months, and she will stop it and call for nausea, fatigue, itching, dark urine or yellow eyes.
Vaginal Symptoms
Handled separately. Low-dose vaginal estrogen has minimal systemic absorption and is not considered to carry the clot risk of systemic therapy, so it can be used for vaginal dryness in women who avoid systemic estrogen (North American Menopause Society, 2022). Offered, with a vaginal moisturizer and lubricant as alternatives; she chose to try the moisturizer first.
What She Was Told
She asked whether she was "missing out" on the best treatment. The answer was honest: estrogen is the most effective treatment for hot flashes, and for many women her age it would be the first choice, but her past clot makes it a riskier choice for her than for most, and there are now nonhormonal options that work well. If fezolinetant and the other options do not give her enough relief, a conversation with a hematologist about transdermal estrogen remains open; nothing is ruled out forever.
She also asked about supplements she had seen advertised. Black cohosh, soy isoflavones and similar products were discussed; the 2023 nonhormone statement does not recommend them for hot flashes because the evidence does not show consistent benefit, and some carry their own risks, including liver effects, which matter while she takes a drug that requires liver monitoring (North American Menopause Society, 2023). She agreed not to add any while starting fezolinetant.
Practical measures were offered alongside the drug: layered clothing, a fan at her desk and bedside, keeping the bedroom cool, and noting triggers such as alcohol and hot drinks in her diary.
Monitoring
1. Liver tests: baseline, then monthly for three months.
2. Hot flash diary: repeat at [three] months; success is a reduction of at least half.
3. Sleep: review with the cognitive behavioral therapy provider at [six] weeks.
4. Mammography: continue on schedule.
5. If fezolinetant fails or is not tolerated: gabapentin at bedtime or low-dose paroxetine next; hematology consultation before any systemic estrogen.
References
Lederman, S., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., English, M., Franklin, C., Lee, M., & Neal-Perry, G. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study. The Lancet, 401(10382), 1091-1102. https://doi.org/10.1016/S0140-6736(23)00085-5
North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590. https://doi.org/10.1097/GME.0000000000002200
How this NU576 Unit 9 example is structured
Three deciding facts organize the first half: timing, symptoms and risk, each in its own paragraph with the finding that settles it. The options table comes only after all three are on the page, which keeps the choice answerable to them. Her prior provoked deep vein thrombosis is the fact that moves systemic estrogen out of first place, and the plan says so plainly rather than listing hormone therapy with a caution. The nonhormonal options are then compared on mechanism, evidence, adverse effects and fit with her other medicines, following the 2023 nonhormone statement. The choice is argued in one paragraph, and the monitoring it requires, including liver tests for the neurokinin 3 receptor antagonist, is set out with dates. Vaginal symptoms are handled separately, because low-dose vaginal estrogen carries a different risk from systemic therapy. Monitoring closes the plan: a review at three months, the symptom count repeated, and mammography kept on schedule.
Get an NU576 Unit 9 example written to your instructions
Upload the menopause case from your NU576 unit together with its rubric. A care plan comes back weighing timing, symptoms and risk before any therapy is named, with each agent and dose bracketed and the 2022 position statement cited accurately, plus a review date. First requests are free and arrive in 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU576 Unit 9 questions, answered
Is the organization called NAMS or The Menopause Society?
Both names appear in the literature. The North American Menopause Society renamed itself The Menopause Society in 2023, after publishing its 2022 hormone therapy position statement under the older name. A reference list can cite the statement as published and mention the current name in the text, which avoids confusion for a grader checking the source.
Does every plan need a nonhormonal option?
Most rubrics expect alternatives to be discussed, even when hormone therapy is chosen, because shared decision-making requires them. The 2023 nonhormone position statement lists options with evidence ratings. Include at least one prescription alternative and one behavioral option, and explain why the patient chose as she did. Where a contraindication rules hormones out, the nonhormonal section becomes the plan itself.
How should the plan handle duration of therapy?
As an individual decision reviewed over time. The 2022 statement does not require stopping at a set age, and it discourages routine discontinuation at sixty-five when benefits continue. A strong plan states the first review date, what will be reassessed, and what would prompt a change in dose, route or approach.